196 related articles for article (PubMed ID: 28600556)
1. Aldose reductase inhibitor increases doxorubicin-sensitivity of colon cancer cells and decreases cardiotoxicity.
Sonowal H; Pal PB; Wen JJ; Awasthi S; Ramana KV; Srivastava SK
Sci Rep; 2017 Jun; 7(1):3182. PubMed ID: 28600556
[TBL] [Abstract][Full Text] [Related]
2. Aldose reductase inhibitor, fidarestat prevents doxorubicin-induced endothelial cell death and dysfunction.
Sonowal H; Pal P; Shukla K; Saxena A; Srivastava SK; Ramana KV
Biochem Pharmacol; 2018 Apr; 150():181-190. PubMed ID: 29458045
[TBL] [Abstract][Full Text] [Related]
3. Aldose reductase inhibitor, fidarestat regulates mitochondrial biogenesis via Nrf2/HO-1/AMPK pathway in colon cancer cells.
Shukla K; Sonowal H; Saxena A; Ramana KV; Srivastava SK
Cancer Lett; 2017 Dec; 411():57-63. PubMed ID: 28986187
[TBL] [Abstract][Full Text] [Related]
4. Nilotinib reverses ABCB1/P-glycoprotein-mediated multidrug resistance but increases cardiotoxicity of doxorubicin in a MDR xenograft model.
Zhou ZY; Wan LL; Yang QJ; Han YL; Li D; Lu J; Guo C
Toxicol Lett; 2016 Sep; 259():124-132. PubMed ID: 27491883
[TBL] [Abstract][Full Text] [Related]
5. Aldose reductase inhibition suppresses colon cancer cell viability by modulating microRNA-21 mediated programmed cell death 4 (PDCD4) expression.
Saxena A; Shoeb M; Ramana KV; Srivastava SK
Eur J Cancer; 2013 Oct; 49(15):3311-9. PubMed ID: 23827854
[TBL] [Abstract][Full Text] [Related]
6. Oxaliplatin resistance in colorectal cancer cells is mediated via activation of ABCG2 to alleviate ER stress induced apoptosis.
Hsu HH; Chen MC; Baskaran R; Lin YM; Day CH; Lin YJ; Tu CC; Vijaya Padma V; Kuo WW; Huang CY
J Cell Physiol; 2018 Jul; 233(7):5458-5467. PubMed ID: 29247488
[TBL] [Abstract][Full Text] [Related]
7. Aldose reductase regulates doxorubicin-induced immune and inflammatory responses by activating mitochondrial biogenesis.
Sonowal H; Saxena A; Qiu S; Srivastava S; Ramana KV
Eur J Pharmacol; 2021 Mar; 895():173884. PubMed ID: 33482179
[TBL] [Abstract][Full Text] [Related]
8. Inhibition of aldose reductase prevents growth factor-induced G1-S phase transition through the AKT/phosphoinositide 3-kinase/E2F-1 pathway in human colon cancer cells.
Ramana KV; Tammali R; Srivastava SK
Mol Cancer Ther; 2010 Apr; 9(4):813-24. PubMed ID: 20354121
[TBL] [Abstract][Full Text] [Related]
9. Doxorubicin treatment modulates chemoresistance and affects the cell cycle in two canine mammary tumour cell lines.
Levi M; Salaroli R; Parenti F; De Maria R; Zannoni A; Bernardini C; Gola C; Brocco A; Marangio A; Benazzi C; Muscatello LV; Brunetti B; Forni M; Sarli G
BMC Vet Res; 2021 Jan; 17(1):30. PubMed ID: 33461558
[TBL] [Abstract][Full Text] [Related]
10. Aldose reductase regulates growth factor-induced cyclooxygenase-2 expression and prostaglandin E2 production in human colon cancer cells.
Tammali R; Ramana KV; Singhal SS; Awasthi S; Srivastava SK
Cancer Res; 2006 Oct; 66(19):9705-13. PubMed ID: 17018629
[TBL] [Abstract][Full Text] [Related]
11. PI3K inhibition enhances doxorubicin-induced apoptosis in sarcoma cells.
Marklein D; Graab U; Naumann I; Yan T; Ridzewski R; Nitzki F; Rosenberger A; Dittmann K; Wienands J; Wojnowski L; Fulda S; Hahn H
PLoS One; 2012; 7(12):e52898. PubMed ID: 23300809
[TBL] [Abstract][Full Text] [Related]
12. Resveratrol enhances chemosensitivity of doxorubicin in multidrug-resistant human breast cancer cells via increased cellular influx of doxorubicin.
Kim TH; Shin YJ; Won AJ; Lee BM; Choi WS; Jung JH; Chung HY; Kim HS
Biochim Biophys Acta; 2014 Jan; 1840(1):615-25. PubMed ID: 24161697
[TBL] [Abstract][Full Text] [Related]
13. Aldose Reductase Inhibitor Fidarestat as a Promising Drug Targeting Autophagy in Colorectal Carcinoma: a Pilot Study.
Pandey S
Asian Pac J Cancer Prev; 2015; 16(12):4981-5. PubMed ID: 26163626
[TBL] [Abstract][Full Text] [Related]
14. Doxorubicin-loaded red blood cells reduced cardiac toxicity and preserved anticancer activity.
Lucas A; Lam D; Cabrales P
Drug Deliv; 2019 Dec; 26(1):433-442. PubMed ID: 30929538
[TBL] [Abstract][Full Text] [Related]
15. Treatment of resistant human colon cancer xenografts by a fluoxetine-doxorubicin combination enhances therapeutic responses comparable to an aggressive bevacizumab regimen.
Argov M; Kashi R; Peer D; Margalit R
Cancer Lett; 2009 Feb; 274(1):118-25. PubMed ID: 18851896
[TBL] [Abstract][Full Text] [Related]
16. Aldose Reductase Inhibitor, Fidarestat Prevents High-fat Diet-induced Intestinal Polyps in Apc
Saxena A; Tammali R; Ramana KV; Srivastava SK
Curr Cancer Drug Targets; 2018; 18(9):905-911. PubMed ID: 28786349
[TBL] [Abstract][Full Text] [Related]
17. Inhibition of aldose reductase prevents colon cancer metastasis.
Tammali R; Reddy AB; Saxena A; Rychahou PG; Evers BM; Qiu S; Awasthi S; Ramana KV; Srivastava SK
Carcinogenesis; 2011 Aug; 32(8):1259-67. PubMed ID: 21642355
[TBL] [Abstract][Full Text] [Related]
18. Effect of ceritinib (LDK378) on enhancement of chemotherapeutic agents in ABCB1 and ABCG2 overexpressing cells in vitro and in vivo.
Hu J; Zhang X; Wang F; Wang X; Yang K; Xu M; To KK; Li Q; Fu L
Oncotarget; 2015 Dec; 6(42):44643-59. PubMed ID: 26556876
[TBL] [Abstract][Full Text] [Related]
19. Visfatin mediates doxorubicin resistance in human colorectal cancer cells via up regulation of multidrug resistance 1 (MDR1).
Yan X; Zhao J; Zhang R
Cancer Chemother Pharmacol; 2017 Aug; 80(2):395-403. PubMed ID: 28667355
[TBL] [Abstract][Full Text] [Related]
20. Quantification of the expression of multidrug resistance-related genes in human tumour cell lines grown with free doxorubicin or doxorubicin encapsulated in polyisohexylcyanoacrylate nanospheres.
Laurand A; Laroche-Clary A; Larrue A; Huet S; Soma E; Bonnet J; Robert J
Anticancer Res; 2004; 24(6):3781-8. PubMed ID: 15736412
[TBL] [Abstract][Full Text] [Related]
[Next] [New Search]
